Skip to main content
S&P 5007,653.91+0.97%DOW52,368.06+1.15%NASDAQ25,767.75+1.30%BTC$77,829.00-0.21%ETH$2,285.89+0.81%GOLD$3,962.10+1.62%OIL$97.45-6.41%
Smart Investors Daily
SID Premium
BI

NASDAQ · BIOA

BioAge Labs, Inc.

Healthcare · Biotechnology

$5.87

Down-$0.20 (-3.32%)

Updated Nov 2, 2026, 3:45 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
458.05M
P/E ratio
-6.04
Dividend yield
0.00%
52-week range
$4.81 – $25.96
Volume
801.36K
Avg. volume
403.63K

Price performance · BIOA

BIOA price history

1M range · 0 trading sessions · Daily adjusted prices

BIOA does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest BIOA news

The latest Smart Investors Daily articles mentioning BIOA.

Stock researchCompany · Overview

BIOA research

Overview

Company profile and research snapshot.

Company profile

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$12.00
Implied upside
—
Analysts
—
BIOA recent ratings
DateFirmRatingTarget
Oct 12, 2026UBSNeutral—
Sep 9, 2026Roth CapitalBuy—
Sep 8, 2026BTIGBuy—
Aug 6, 2026BTIGBuy—
Aug 3, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 14, 2026

Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target

Partnership applies Deep Origin's virtual screening architecture to BioAge's targets, identified from human data, to accelerate discovery of novel cardiometabolic therapiesSOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Deep Origin today announced a multi-target AI-driven drug discovery collaboration with BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of hu

Yahoo · Sep 25, 2026

BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: • ROTH Healthcare Opportunities Conference (New York, September 29, 2026): BJ Sullivan, Dov Goldstein, MD, CFO, and Alexis Jakubowski, A

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By